BPMC (Blueprint Medicines Corporation) רווח למניה בארבעת הרבעונים האחרונים

Blueprint Medicines ensures the seamless delivery of innovations through proven partners, expanding the presence of Ayvakit in oncology. The TTM EPS annual growth rate visualizes the financial trend, where the 10.40 metric indicates the profitability status. A monopoly position and patent protection for orphan drugs allow the company to flexibly manage pricing power, minimizing pressure from generics.
Blueprint Medicines Corp - פילוחים אנליטיים ומדדי מפתח (BPMC)

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of rolling annual earnings per share, separating accounting reports from market value. By analyzing the current YoY TTM EPS growth rate, an investor assesses the real efficiency of capital generation between quarterly reports. This metric captures the rate of change in net income, reflecting the fundamental return of the business. For Blueprint Medicines (BPMC), this indicator confirms the monetization of its unique molecule discovery platform. The scalability of patents allows the company to transform approved drugs into global superprofits.